JPET

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Aicher, S. A.
Right arrow Articles by Drake, C. T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Aicher, S. A.
Right arrow Articles by Drake, C. T.

Vol. 289, Issue 2, 688-694, May 1999

Clonidine Evokes Vasodepressor Responses via alpha 2-Adrenergic Receptors in Gigantocellular Reticular Formation1

Sue A. Aicher and Carrie T. Drake

Department of Neurology and Neuroscience, Division of Neurobiology, Cornell University Medical College, New York, New York

The gigantocellular depressor area (GiDA) is a functionally defined subdivision of the medullary gigantocellular reticular formation where vasodepressor responses are evoked by glutamate nanoinjections. The GiDA also contains reticulospinal neurons that contain the alpha 2A-adrenergic receptor (alpha 2A-AR). In the present study, we sought to determine whether nanoinjections of the alpha 2-AR agonist clonidine into the GiDA evoke cardiovascular responses and whether these responses can be attributed to the alpha 2-AR. We found that nanoinjections of clonidine into the GiDA evoke dose-dependent decreases in arterial pressure and heart rate. These responses were equivalent in magnitude to responses produced by clonidine nanoinjections into the sympathoexcitatory region of the rostral ventrolateral medulla. Furthermore, the vasodepressor and bradycardic responses produced by clonidine injections into the GiDA were blocked in a dose-dependent fashion by the highly selective alpha 2-AR antagonist 2-methoxyidazoxan, but not by prazosin, which is an antagonist at both the alpha 1-AR and the 2B subtype of the alpha -AR. The antagonism by 2-methoxyidazoxan was site specific because injections of the antagonist into the rostral ventrolateral medulla failed to block the responses evoked by clonidine injections into the GiDA. These findings support the notion that clonidine produces sympathoinhibition through multiple sites within the medullary reticular formation, which is consistent with the wide distribution of the alpha 2A-AR in reticulospinal neurons. These data also suggest that clonidine may have multiple mechanisms of action because it evokes a cardiovascular depressive response from regions containing neurons that have been determined to be both sympathoinhibitory and sympathoexcitatory.


0022-3565/99/2892-0688$03.00/0
THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
Copyright © 1999 by The American Society for Pharmacology and Experimental Therapeutics



This article has been cited by other articles:


Home page
Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
R. G. Menegaz, D. R. Kapusta, H. Mauad, and A. de Melo Cabral
Activation of {alpha}2-receptors in the rostral ventrolateral medulla evokes natriuresis by a renal nerve mechanism
Am J Physiol Regulatory Integrative Comp Physiol, July 1, 2001; 281(1): R98 - R107.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
A. M. Schreihofer and P. G. Guyenet
Role of presympathetic C1 neurons in the sympatholytic and hypotensive effects of clonidine in rats
Am J Physiol Regulatory Integrative Comp Physiol, November 1, 2000; 279(5): R1753 - R1762.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 1999 by the American Society for Pharmacology and Experimental Therapeutics.